Prednisone Pill

Phase 1Small molecule

Prednisone Pill is one of 7 small molecule programs targeting Relapsed/Refractory B-cell ALL. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed/refractory B-Cell ALLActive, not recruiting

Relapsed/refractory B-Cell ALLPhase 1

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Relapsed/refractory B-Cell ALL

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Phase 1

1 2

Oncovin

Eli Lilly

Phase 1

1 3

Cytosar

Teva

Phase 1

1 4

Oncaspar

SServier

Phase 1

1 5

Besponsa

WWyeth-Lederle Vaccines

Phase 1

1 6

Cerubidine

HHikma Pharmaceuticals LLC

Phase 1

1 7

Prednisone Pill

UUniversity of Virginia

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Relapsed/Refractory B-cell ALL1 trial

Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL

Active, not recruiting·UUniversity of Virginia·Phase 1·NCT03962465·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Prednisone Pill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Prednisone Pill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Prednisone Pill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Virginia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Virginia

Prednisone Pill

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Relapsed/Refractory B-cell ALL1 trial

References

Drug Info

Quick Facts

Related News